<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="169">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00003141</nctid>
  <trial_identification>
    <studytitle>Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors</studytitle>
    <scientifictitle>A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>COG-99703</secondaryid>
    <secondaryid>99703</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain Tumors</healthcondition>
    <healthcondition>Central Nervous System Tumors</healthcondition>
    <healthcondition>Neuroblastoma</healthcondition>
    <healthcondition>Sarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Other</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - filgrastim
Treatment: drugs - carboplatin
Treatment: drugs - cisplatin
Treatment: drugs - cyclophosphamide
Treatment: drugs - etoposide
Treatment: drugs - thiotepa
Treatment: drugs - vincristine sulfate
Treatment: surgery - conventional surgery
Treatment: surgery - peripheral blood stem cell transplantation

Experimental: Treatment (combination chemotherapy, PBSC transplant) - Pts undergo conventional surgery for diagnosis &amp; max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) &amp; undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.


Other interventions: filgrastim
Given IV

Treatment: drugs: carboplatin
Given IV

Treatment: drugs: cisplatin
Given IV

Treatment: drugs: cyclophosphamide
Given IV

Treatment: drugs: etoposide
Given IV

Treatment: drugs: thiotepa
Given IV

Treatment: drugs: vincristine sulfate
Given IV

Treatment: surgery: conventional surgery


Treatment: surgery: peripheral blood stem cell transplantation


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Feasibility - Demonstrate the feasibility of administering this regimen, to select an acceptable Thiotepa dose for Consolidation therapy, and to document significant toxicities and estimate their overall rates</outcome>
      <timepoint>Up to 4 weeks after completion of study treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximal tolerated dose of thiotepa for consolidation therapy - The dose level will be assigned within 3 working days prior to beginning Consolidation.</outcome>
      <timepoint>9 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall rates of significant toxicities including grade IV ototoxicity, electrolytic wasting (grade IV), and hemorrhagic cystitis (grade IV) - Estimates will be obtained using life-table methods with an event defined as the first occurrence of toxicity. Graded using the CCG Toxicity and Complications Criteria.</outcome>
      <timepoint>Up to 6 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Event Free Survival</outcome>
      <timepoint>From the time of study entry to the first occurrence of death by any cause, progression or recurrence of disease or occurrence of a second malignant neoplasm, assessed up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically proven malignant brain or spinal cord tumor, including the following:

               -  Primitive neuroectodermal tumor

               -  Ganglioneuroblastoma

               -  Medulloblastoma neuroblastoma

               -  Desmoplastic medulloblastoma

               -  Medulloepithelioma

               -  Ependymoma neuroepithelioma

               -  Anaplastic ependymoma germ cell tumor

               -  Astrocytoma germinoma

               -  Anaplastic astrocytoma

               -  Embryonal carcinoma

               -  Glioblastoma endodermal sinus tumor

               -  Gliosarcoma malignant teratoma

               -  Choroid plexus carcinoma

               -  Mixed germ cell tumor

               -  Cerebellar sarcoma

               -  Pineoblastoma

               -  Atypical teratoid/rhabdoid tumor

               -  Choriocarcinoma

               -  Teratoma (malignant or with malignant transformations)

          -  Diffusely involved brain stem tumors allowed if there is evidence of brain stem glioma
             by CT scan or MRI

        PATIENT CHARACTERISTICS:

        Age:

          -  6 months to less than 3 years

        Performance Status:

          -  Not specified

        Life Expectancy:

          -  More than 8 weeks

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 2.0 mg/dL

        Renal:

          -  Glomerular filtration rate or creatinine clearance greater than 70 mL/min

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Prior corticosteroids allowed

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  No more than 6 weeks since prior surgery

          -  Recovered from prior surgery (stable)</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>2</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/1998</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>94</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctors to give higher doses of chemotherapy drugs and kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral
      stem cell transplantation in treating infants with malignant brain or spinal cord tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00003141</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bruce H. Cohen, MD</name>
      <address>The Cleveland Clinic</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>